Fundraising Fox
Animerra
Boston, US · Founded 2024 · Delaware corporation · 1 known investors
Find your way into Animerra
Sign up to see every warm intro you have to Animerra
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Animerra team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Animerra develops next-generation biologics for companion animal health, applying therapeutic innovation from human medicine to veterinary treatment. The company targets pet owners and veterinary markets with innovative protein-based therapeutics and biologics treatments.
Founders & leadership
AR
Investors · 1
Anterra Capital✓ confirmed by AnimerraAmsterdam · $20M
How we know: the company's own site · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$6.5M disclosed across 1 round · 2025
▶$6.5MraisedFeb 2025 · 1 investors · Other Health CareRule 506(b)
▶$6.5MraisedFeb 2025 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Anna RathExecutive Officer
- Offering amount
- $20M
- Amount sold
- $6.5M
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 6
ANI PharmaceuticalsANI Pharmaceuticals is a generic and specialty pharmaceutical company that develops, manufactures, and distributes prescription drugs across multiple therapeutic areas including generics, rare diseases, and established branded products.
VISTERRA, INC.A biologics center of excellence focused on developing and delivering medicines to patients, operating as a subsidiary within the Otsuka pharmaceutical group.
InvenraInvenra develops proprietary platform technologies to discover and develop novel bi- and multi-specific antibody therapies, with an initial focus on oncology. The company is advancing pipelines of antibody candidates with partners and intends to expand into additional disease categories.
BIOVECTRABIOVECTRA is a contract development and manufacturing organization (CDMO) with research and development capabilities in biologics process development, complex chemistry, and analytical development. Its work spans recombinant proteins, viral vectors, mRNA vaccines, and pharmaceutical process development for the biotech and pharmaceutical industries.
Neumora TherapeuticsNeumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.
AzitraAzitra is a clinical-stage biopharmaceutical company developing genetically engineered bacteria and proteins for treating skin diseases through precision dermatology. The company leverages a proprietary platform combining a microbial library of approximately 1,500 bacterial strains with AI/ML-powered screening and genetic engineering technology.
Companies working in the same space as Animerra.
Frequently asked questions
- What does Animerra do?
- Animerra develops next-generation biologics for companion animal health, applying therapeutic innovation from human medicine to veterinary treatment. The company targets pet owners and veterinary markets with innovative protein-based therapeutics and biologics treatments.
- Who are Animerra's investors?
- Animerra's investors include Anterra Capital.
- How much funding has Animerra raised?
- Animerra has disclosed $6.5M raised across 1 round.
- Where is Animerra headquartered?
- Animerra is headquartered in Boston, US.